CSBR (Champions Oncology) LT-Debt-to-Total-Asset: 0.12 (As of Jan. 2026)

What is Champions Oncology LT-Debt-to-Total-Asset?

Champions Oncology CSBR +3.08% 64 LT-Debt-to-Total-Asset is 0.12 as of Jan. 2026. GuruFocus rates CSBR with a GF Score™ of 64/100 and a GF Value™ of $6.62 (Fairly Valued). The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Champions Oncology's long-term debt to total assests ratio for the quarter that ended in Jan. 2026 was 0.12.

Champions Oncology's long-term debt to total assets ratio declined from Jan. 2025 (0.16) to Jan. 2026 (0.12). It may suggest that Champions Oncology is progressively becoming less dependent on debt to grow their business.

Champions Oncology (NAS:CSBR) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Champions Oncology LT-Debt-to-Total-Asset Related Terms

Champions Oncology LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Champions Oncology's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology LT-Debt-to-Total-Asset Chart

Champions Oncology Annual Data

Trend

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

Apr25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.32

0.24

0.22

0.23

0.14

Champions Oncology Quarterly Data
	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25	Apr25	Jul25	Oct25	Jan26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.16	0.14	0.14	0.12	0.12

64GF Score

Champions Oncology Inc CSBR

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Champions Oncology LT-Debt-to-Total-Asset Calculation

Champions Oncology's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Apr. 2025 is calculated as

LT Debt to Total Assets (A: Apr. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Apr. 2025 )	/	Total Assets (A: Apr. 2025 )
	=	4.634	/	32.344
	=	0.14

Champions Oncology's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2026 is calculated as

LT Debt to Total Assets (Q: Jan. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jan. 2026 )	/	Total Assets (Q: Jan. 2026 )
	=	3.365	/	28.447
	=	0.12

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.12 mean?

Champions Oncology (CSBR) has a LT-Debt-to-Total-Asset of 0.12 as of Jan. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Champions Oncology and its competitors.

Is Champions Oncology's LT-Debt-to-Total-Asset too high?

Champions Oncology's current LT-Debt-to-Total-Asset is 0.12. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Champions Oncology's LT-Debt-to-Total-Asset compare to SEER and RLYB?

Champions Oncology's LT-Debt-to-Total-Asset of 0.12 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Champions Oncology and its competitors. Champions Oncology's current LT-Debt-to-Total-Asset is 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Champions Oncology stock overvalued right now?

Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.62, compared to a current price of $6.36 — trading 3.9% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.12. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Champions Oncology (CSBR), the current LT-Debt-to-Total-Asset is 0.12 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Champions Oncology (CSBR) Overvalued in 2026?

Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued. The current stock price of $6.36 is trading 3.9% below its estimated GF Value™ of $6.62. GuruFocus considers Champions Oncology to be Fairly Valued.

Key valuation signals for CSBR:

LT-Debt-to-Total-Asset: 0.12
GF Value™: $6.62 vs. price of $6.36 (3.9% below fair value)
GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Champions Oncology Business Description

Industry Healthcare Biotechnology

Comparable Companies SEER RLYB FBIO INO NRXS ATRA PYPD ANIX BMEA PMN VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address One University Plaza, Suite 307, Hackensack, NJ, USA, 07601

Website https://www.championsoncology.com

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

64GF Score

Get the complete analysis for CSBR

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.36

Price

$6.62

GF Value

View CSBR Analysis

See LT-Debt-to-Total-Asset data for all stocks →